VRAYLAR 3 MG — DIN 02526808
CARIPRAZINE (CARIPRAZINE HYDROCHLORIDE) : 3 MG · ABBVIE CORPORATION · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is VRAYLAR?
VRAYLAR 3 MG contains CARIPRAZINE (CARIPRAZINE HYDROCHLORIDE) : 3 MG. It is listed in the Health Canada Drug Product Database under DIN 02526808, held by ABBVIE CORPORATION, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 14-May-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VRAYLAR used for?
VRAYLAR (cariprazine) is indicated for: • the treatment of schizophrenia in adults. In controlled clinical trials, VRAYLAR was found to improve both positive and negative symptoms. Bipolar I disorder VRAYLAR is indicated as monotherapy for: • Bipolar Mania: acute management of manic or mixed episodes associated with bipolar I disorder in adults, and • Bipolar Depression: acute management of depressive episodes associated with bipolar I disorder in adults. The efficacy of VRAYLAR for long-term use has not been systematically evaluated in controlled studies for bipolar mania and depression. The physician who elects to use VRAYLAR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cariprazine cost around the world?
Cariprazine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Hungary | producer price (ex-factory) | 8 | 8 | HUF███.██ |
| Australia | ex-manufacturer | 1 | 4 | AUD███.██ |
| Greece | producer price (ex-factory) | 4 | 4 | EUR███.██ |
| Iceland | max wholesale | 1 | 4 | ISK███.██ |
20 pack listings across 14 brand entries and 3 price bases, refreshed 08 Sep 2026. Ranges span every Cariprazine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cariprazine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Cariprazine — 4 DINs, of which 4 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ABBVIE CORPORATION | 4 | 4 | VRAYLAR | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 3 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 30 capsules: 1.5 mg, 3 mg, 4.5 mg and 6 mg. Physician's Sample available as a blister of 7 capsules: 1.5 mg, 3 mg, 4.5 mg and 6 mg. |
| Storage | Store between 15 and 30°C. Protect the 3 mg and 4.5 mg capsules from light to prevent potential color fading. Keep out of reach and sight of children. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cariprazine |
|---|---|
| ATC code | N05AX15 |
| AHFS class | 28:16.08.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02526808 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2526808 |
| Brand name | VRAYLAR |
| Generic / active ingredient | CARIPRAZINE (CARIPRAZINE HYDROCHLORIDE) : 3 MG |
| Market authorization holder | ABBVIE CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | N05AX15 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05AX |
| Current status | MARKETED |
| Status date | 14-May-2024 |
| Original market date | 2022-06-24 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
VRAYLAR is given orally once daily and can be taken with or without food. The usual starting dose is 1.5 mg, once a day. Schizophrenia: The recommended target dosage for VRAYLAR is 1.5 mg to 6 mg once daily. The dosage can be increased gradually in 1.5 mg increments. The maximum recommended dosage is 6 mg daily. Bipolar Mania: The recommended dosage range is 1.5 mg to 6 mg once daily. The starting dose is 1.5 mg and can be increased thereafter by 1.5 mg increments. The maximum recommended dosage is 6 mg daily. Bipolar Depression: The recommended dose is 1.5 mg once daily. The dosage can be increased to 3 mg once daily on Day 15. The maximum recommended dosage is 3 mg once daily. Missed Dose: If a patient misses a dose by a few hours, they should take it as soon as remembered. If most of the day has passed, they should wait until the next scheduled dose. Do not take 2 doses at once. Due to the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks. Prescribers should monitor patients for adverse reactions and treatment response for several weeks after starting VRAYLAR and after each dosage change.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
VRAYLAR is contraindicated: • in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. • With concomitant use of strong and moderate CYP3A4 inhibitors. Due to the slow elimination of cariprazine and its metabolites, treatment with strong and moderate CYP3A4 inhibitors must be initiated at least 2 weeks after VRAYLAR discontinuation. • With concomitant use of strong and moderate CYP3A4 inducers.
Warnings and precautions
Increased Mortality in Elderly Patients with Dementia: Elderly patients with dementia treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. VRAYLAR is not approved for the treatment of patients with dementia-related psychosis. Late-Occurring Adverse Reactions: Adverse events may first appear several weeks after the initiation of VRAYLAR treatment, likely because plasma levels of cariprazine and its major metabolites accumulate over time. Monitor for adverse reactions, including extrapyramidal symptoms (EPS) or akathisia, and patient response for several weeks after starting VRAYLAR and after each dosage increase. Consider reducing the dose or discontinuing the drug. Neuroleptic Malignant Syndrome (NMS): A potentially fatal symptom complex reported with antipsychotic drugs. Immediately discontinue VRAYLAR if NMS is suspected. Tardive Dyskinesia: A syndrome of potentially irreversible, involuntary, dyskinetic movements. Risk increases with duration of treatment and cumulative dose. Use the lowest dose and shortest duration for satisfactory clinical response. Discontinuation should be considered if signs appear. Suicide/Suicidal Thoughts or Clinical Worsening: Depressive episodes are associated with an increased risk of suicidal thoughts, self-harm, and suicide. Monitor patients closely until improvement occurs. Schizophrenia and manic episodes also carry an increased risk of suicide-related events. Counsel family members/caregivers to monitor for behavioral changes. Pregnancy: Women of childbearing potential must be advised to use highly effective contraceptive methods during treatment and for at least 12 weeks following discontinuation. VRAYLAR is not recommended during pregnancy unless benefits outweigh risks to the fetus.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| VRAYLAR | 1.5 MG | CAPSULE | ABBVIE CORPORATION | MARKETED | 02526794 |
| VRAYLAR | 4.5 MG | CAPSULE | ABBVIE CORPORATION | MARKETED | 02526816 |
| VRAYLAR | 6 MG | CAPSULE | ABBVIE CORPORATION | MARKETED | 02526824 |
2 · Same class — other molecules in ATC N05AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Aripiprazole | ABILIFY · ABILIFY ASIMTUFII · ABILIFY MAINTENA · AG-ARIPIPRAZOLE · +14 more | 105 | 83 | Yes |
| Risperidone | ACT RISPERIDONE · AG-RISPERIDONE · APO-RISPERIDONE · AVA-RISPERIDONE · +37 more | 217 | 71 | Yes |
| Paliperidone | INVEGA · INVEGA SUSTENNA · INVEGA TRINZA · MAR-PALIPERIDONE · +1 more | 18 | 11 | Yes |
| Brexpiprazole | REXULTI | 8 | 6 | Yes |
| Cariprazine | VRAYLAR | 4 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05AH | Asenapine · Clozapine · Loxapine · Olanzapine · Quetiapine | 589 | 220 |
| N05AE | Lurasidone · Ziprasidone | 60 | 41 |
| N05AB | Fluphenazine · Perphenazine · Prochlorperazine · Thioproperazine · Trifluoperazine | 104 | 10 |
| N05AD | Droperidol · Haloperidol | 53 | 9 |
| N05AA | Chlorpromazine · Levomepromazine · Promazine | 51 | 8 |
| N05AF | Flupentixol · Tiotixene · Zuclopenthixol | 25 | 8 |
| N05AN | Lithium | 26 | 7 |
| N05AC | Mesoridazine · Periciazine · Pipotiazine · Thioridazine | 32 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VRAYLAR called?
Also recorded in Canada as: REAGILA (EU), REAGILA (UK), REAGILA (IN), CARIPRAZINE (GLOBAL), CARIPRAZINE (US), CARIPRAZINE (UK), CARIPRAZINE (JP).
The same molecule, Cariprazine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Reagila | Latin | Australia, Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.